ObjectiveTo observe the difference of retinal vessel oxygen saturation in glaucoma and normal eyes. MethodsA cross sectional study design was performed. Fifty eyes of 30 glaucoma patients (glaucoma group) and 41 eyes of 27 age-and sex-matched healthy subjects (control group) were included. Retinal vessel oxygen saturation was measured with a spectrophotometric retinal oximeter in darkness and visual fields were obtained by Humphrey filed analyzer. The glaucoma eyes were divided into two groups: mean defect (MD)<6 dB (28 eyes) and MD≥6 dB (22 eyes) according to mean defect of visual field. ResultsRetinal arteriolar oxygen saturation values in glaucoma group and control group were (94.52±6.51)% and (93.47±6.30)% respectively. No statistical difference was found in retinal oxygen saturation in arterioles (H=-0.949, P=0.343). Retinal venous oxygen saturation values in glaucoma group and control group were (57.57±7.96)% and (52.60±7.70)% respectively. The retinal venous oxygen saturation values in glaucoma group was higher than that in control group (H=-3.318,P=0.001). The retinal arteriovenous difference in glaucoma group and control group were (36.59±4.69)% and (42.41±6.73)% respectively. The retinal arteriovenous difference in glaucoma group was lower than that in control group (H=-4.148,P<0.01). The retinal arteriolar oxygen saturation values in glaucoma eyes with MD<6 dB and MD≥6 dB were (93.38±6.33)% and (95.71±6.54)% respectively, with no statistical difference (H=-1.857,P=0.063). Retinal venous oxygen saturation values in glaucoma eyes with MD<6 dB and MD≥6 dB were (54.83±6.10)% and (61.07±8.79)% respectively. The retinal venous oxygen saturation values in MD≥6 dB glaucoma eyes was higher than that in MD<6 dB glaucoma eyes (H=-2.599, P=0.009). The retinal arteriovenous difference in glaucoma eyes with MD<6 dB and MD≥6 dB were (38.12±4.34)% and (34.64±4.49)% respectively. The retinal arteriovenous difference in MD≥6 dB glaucoma eyes was lower than that in MD<6 dB glaucoma eyes (H=-2.463,P<0.05). ConclusionsCompared with healthy eyes, there is no change in the retinal arteriolar oxygen saturation, but the retinal venous oxygen saturation is higher and the retinal arteriovenous difference is lower. This feature is more obvious in MD≥6 dB glaucoma eyes.
Objective To investigate the correlation between the vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD). Methods A literature research was performed in PubMed, EMbase, Cochrane Library, CNKI and Wanfang database from January 2000 to December 2016. Case-control studies on the relationship between VMA or posterior vitreous detachment and exudative AMD were included in this analysis. Literature screening and data extraction were performed according to inclusion and exclusion criteria. The qualities of the literatures were evaluated according to the Newcastle-Ottawa Scale (NOS). Seven literatures were selected into meta-analysis. The NOS score was 9 points in 1 article, 8 scores in 4 articles, 7 points in 2 articles. A total of 947 eyes with exudative AMD, 638 eyes with dry AMD, and 618 eyes with controls were included. The correlation between exudative AMD and VMA were analyzed using the software Review manager 5.3. Results The prevalence of VMA in exudative AMD eyes was higher than that in controls [odds ratio (OR)=2.14, 95% confidence interval (CI)=1.19 - 3.84, P=0.010] and dry AMD eyes (OR=2.24, 95%CI=1.24 - 4.03, P=0.007). There was no difference in PVD prevalence among exudative AMD eyes, dry AMD eyes (OR=0.44, 95%CI=0.16 - 1.20, P=0.110) and controls (OR=0.70, 95%CI=0.41 - 1.18, P=0.180). Conclusion There is correlation between VMA and exudative AMD.
ObjectiveTo observe the short-term efficacy of posterior sub-tenon injection of triamcinolone acetonide (PSTA) in the treatment of macular edema due to ischemic retinal vein occlusions (RVO). MethodsA retrospective clinical study. A total of 53 eyes of 53 patients with RVO macular edema diagnosed by fundus color photography, fundus fluorescein angiography and optical coherence tomography (OCT) were included in the study. The best corrected visual acuity (BCVA) was detected by the international standard visual acuity chart, and the results were converted to the logarithm of the minimum angle of resolution (logMAR) visual acuity. The central macular thickness (CMT) was measured by OCT. Among 53 eyes, there were 27 eyes with ischemic RVO macular edema (ischemic group) and 26 eyes with non-ischemic RVO macular edema (non-ischemic group). The mean logMAR BCVA was 0.82±0.37, mean CMT was (662.1±216.7) μm in ischemic group. The mean logMAR BCVA was 0.41±0.23, mean CMT was (548.0±161.9) μm. The differences of logMAR BCVA and CMT between the two groups were both statistically significant (t=4.745, 2.258; P<0.05). All eyes were treated with a single sub-Tenon injection of 0.4 ml triamcinolone acetonide suspension (100 mg/ml).The mean logMAR BCVA, CMT before and 1, 3 months after the treatment between the two groups were observed and compared. ResultsOn 1 and 3 months after treatment, the mean logMAR BCVA in the non-ischemic group (0.32±0.25 and 0.27±0.29) were improved compared with ischemic group (0.76±0.37 and 0.41±0.79), the difference was statistically significant (t=5.052, 5.240; P<0.05). The mean logMAR BCVA before and after treatment had no statistically significant difference in ischemic group (F=0.516, P>0.05), but had a statistically significant difference in non-ischemic group (F=7.685, P<0.05). On 1 and 3 months after treatment, the mean CMT in the ischemic group were (534.7±223.4), (470.8±234.7) μm, which were lower (127.4±28.28), (191.4±34.55) μm before treatment. In the non-ischemic group, the average CMT was (426.2±188.8), (371.3±200.6) μm, which were lower (103.1±33.1), (164.9±49.6) μm. There were statistically significant differences in the mean CMT between the ischemic group and the non-ischemic group (F=17.040, 10.360; P<0.05). In non-ischemic group, CMT had a bigger reduction compared to the the ischemic group (t=2.056, 2.103; P<0.05). The difference of CMT decrease value between two groups was not statistically significant (t=0.560, 0.441; P>0.05). On 1 month after the treatment, there were 3 and 5 eyes had a higher intraocular pressure than 21 mmHg (1 mmHg=0.133 kPa) in ischemic and non-ischemic group, respectively; but all of them returned to normal after drug treatment. There were no drugs and ocular injection related complications. ConclusionPSTA of ischemic RVO macular edema can lower the CMT in the short term, but can't significant improve the visual acuity.